Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: Synthesis and preliminary animal and human studies

European Journal of Nuclear Medicine

Volumn 25, Issue 6, 1998, Pages 613-621

  Blower, Philip J ^a,b   Lam, Albert S K ^b   O'Doherty, Michael J ^a   Kettle, Andrew G ^a   Coakley, Anthony J ^a   Knapp Jr , F F ^c  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Bone metastases; Dimercaptosuccinic acid; Medullary thyroid carcinoma; Rhenium 188

Indexed keywords

OXIDRONATE TECHNETIUM TC 99M; RHENIUM 188; SUCCIMER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE; BONE METASTASIS; BONE SCINTISCANNING; BRONCHUS CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; MALE; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PROSTATE CANCER; RADIOTHERAPY; SOFT TISSUE; THYROID MEDULLARY CARCINOMA; URINE;

AGED; AGED, 80 AND OVER; ANIMALS; BONE NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; SUCCIMER; TISSUE DISTRIBUTION;

EID: 0031805406     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050263     Document Type: Article

References (34)

1. Ohta H, Yamamoto K, Endo K, et al. A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 1984; 25: 323-325.
2. Clarke SEM, Lazarus CR, Mistry R, Maisey MN. The role of technetium-99 m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroid. Br J Radiol 1987; 60: 1089-1092.
3. 99mTc(V)-dimercaptosuccinic acid (DMSA) for imaging medullary carcinoma of the thyroid and its metastases. Eur J Nucl Med 1988; 13: 507-510.
4. 99mTc]MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988; 29: 33-38.
5. m dimercaptosuccinic acid, a new tumour-seeking agent. Nucl Med Commun 1988; 9: 105-116.
6. 99mTc(V)DMSA scintigraphy in a case of maxillary sinus liposarcoma. Ann Nucl Med 1993; 7: 61-64.
7. Kobayashi H, Sakahara H, Hosono M, et al. Scintigraphic evaluation of tenosynovial giant cell tumour using technetium-99m(V)-dimercaptosuccinic acid. J Nucl Med 1993; 34: 1745-1747.
8. Kobayashi H, Sakahara H, Hosono M, et al. Soft-tissue tumours: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy. Radiology 1994; 190: 277-280.
9. Ohta H, Endo K, Fujita T, et al. Imaging of head and neck tumours with technetium(V)-99mDMSA: a new tumour-seeking agent. Clin Nucl Med 1985; 10: 855-860.
10. Adams BK, Fataar A, Byrne MJ, Levitt NS, Matley PJ. Pentavalent technetium-99 m (V)-DMSA uptake in a phaeochromocytoma in a patient with Sipple's syndrome. J Nucl Med 1990; 31: 106-108.
11. Hirano T, Otake H, Yoshida I, Endo K. Primary lung cancer SPECT imaging with pentavalent technetium-99m-DMSA. J Nucl Med 1995; 36: 202-207.
12. Kao C-H, Wang S-J, Wey S-P, Shen L-H, Ting G, Yeh S-H. Use of technetium-99m (V) dimercaptosuccinic acid to detect malignancies from single solid masses in the lungs. Eur J Nucl Med 1992; 19: 890-893.
13. Ohta H, Ishii M, Yoshizumi M, et al. Is ECT imaging with Tc(V)-99m dimercaptosuccinic acid useful to detect lung metastases of osteosarcoma? Clin Nucl Med 1985; 10: 13-15.
14. Trapali X, Zissimopoulos A, Baziotis N, et al. The application of Tc99m-V-DMSA in osteosarcoma localisation [abstract]. J Nucl Med 1992; 33: 708.
15. Banzo J, Prats E, Abos MD, et al. Tc-99m(V)-DMSA imaging in patients with bone lesions [abstract]. Eur J Nucl Med 1993; 20: 902.
16. Lam ASK, Kettle AG, O'Doherty MJ, Coakley AJC, Barrington SF, Blower PJ. Pentavalent technetium-99m-DMSA imaging in patients with bone metastases. Nucl Med Commun 1997; 18: 907-914.
17. Blower PJ, Singh J, Clarke SEM. The chemical indentity of pentavalent technetium-99m-DMSA. J Nucl Med 1991; 32: 845-849.
18. 186Re]rhenium(V) dimercaptosuccinic acid: a possible tumour radiotherapy agent. Appl Radiat Isot 1991; 42: 167-171.
19. 2 dmsa=meso-2,3-dimercaptosuccinic acid). J Chem Soc, Chem Commun 1991; 1115-1117.
20. 188Re]-pentavalent rhenium dimercaptosuccinic acid complex. Nucl Med Commun 1993; 14: 197-203.
21. 186Re DMSA: a possible tumour therapy agent. J Nucl Med 1990; 31: 768.
22. 99mTc-dimercaptosuccinic acid. Eur J Nucl Med 1996; 23: 1575-1582.
23. 188Relabeled radiopharmaceuticals for cancer treatment. Anticancer Res 1997; 17: 1783-1796.
24. m generator: a simple and convenient method for concentrating generator eluate for clinical use. Nucl Med Commun 1993; 14: 995-997.
25. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
26. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Parry Howells G, Tipton IH. Report of the Task Group on Reference Man (ICRP no. 23). Oxford, UK: Pergamon, 1975.
27. Madrazo A, Schwarz G, Churg J. Radiation nephritis: a review. J Urol 1975; 114: 822-827.
28. Flower MA, McCready VR. Radionuclide therapy dose calculations: what accuracy can be achieved? Eur J Nucl Med 1997; 24: 1462-1464.
29. 186Re-DMSA offers potential for tumour-targeted radiotherapy of medullary thyroid carcinoma (MTC). Nucl Med Commun 1992; 13: 211.
30. 186Re-HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646-651.
31. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 1994; 30: 1187-1194.
32. Bayouth JE, Macey DJ, Kasi LP, Fossells FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain to skeletal metastases. J Nucl Med 1994; 35: 63-69.
33. Blake GM, Zivanovic MA, McEwan AJ et al. Strontium-89 radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 1987; 13: 41-46.
34. Lin W-Y, Lin C-P, Yeh S-J, et al. Rhenium-188 hydroxymethylene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 1997; 24: 590-595.